These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7734321)

  • 1. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
    Tsutsumi Y; Kihira T; Tsunoda S; Kanamori T; Nakagawa S; Mayumi T
    Br J Cancer; 1995 May; 71(5):963-8. PubMed ID: 7734321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.
    Tsutsumi Y; Kihira T; Yamamoto S; Kubo K; Nakagawa S; Miyake M; Horisawa Y; Kanamori T; Ikegami H; Mayumi T
    Jpn J Cancer Res; 1994 Jan; 85(1):9-12. PubMed ID: 8106293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
    Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
    Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
    Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    Br J Cancer; 1996 Oct; 74(7):1090-5. PubMed ID: 8855980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
    Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
    J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha.
    Kamada H; Tsutsumi Y; Tsunoda S; Kihira T; Kaneda Y; Yamamoto Y; Nakagawa S; Horisawa Y; Mayumi T
    Biochem Biophys Res Commun; 1999 Apr; 257(2):448-53. PubMed ID: 10198233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-alpha completely regressed solid tumor in Meth-A murine sarcoma model.
    Tsutsumi Y; Kihira T; Tsunoda S; Kubo K; Miyake M; Kanamori T; Nakagawa S; Mayumi T
    Jpn J Cancer Res; 1994 Dec; 85(12):1185-8. PubMed ID: 7852179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
    Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.
    Tsutsumi Y; Tsunoda S; Kaneda Y; Kamada H; Kihira T; Nakagawa S; Yamamoto Y; Horisawa Y; Mayumi T
    Jpn J Cancer Res; 1996 Oct; 87(10):1078-85. PubMed ID: 8957067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
    Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
    Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.
    Dai C; Fu Y; Chen S; Li B; Yao B; Liu W; Zhu L; Chen N; Chen J; Zhang Q
    Sci China Life Sci; 2013 Jan; 56(1):51-8. PubMed ID: 23314867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
    Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
    Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
    Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
    Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
    Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
    J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective enhancer of tumor vascular permeability for optimization of cancer chemotherapy.
    Yoshioka Y; Tsutsumi Y; Kamada H; Kihira T; Tsunoda S; Yamamoto Y; Okamoto T; Shibata H; Mukai Y; Taniai M; Shimizu T; Kawamura M; Abe Y; Nakagawa S; Mayumi T
    Biol Pharm Bull; 2004 Mar; 27(3):437-9. PubMed ID: 14993819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol).
    Vugmeyster Y; Entrican CA; Joyce AP; Lawrence-Henderson RF; Leary BA; Mahoney CS; Patel HK; Raso SW; Olland SH; Hegen M; Xu X
    Bioconjug Chem; 2012 Jul; 23(7):1452-62. PubMed ID: 22731748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects.
    Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Gao XJ; Zhu JH
    Biol Pharm Bull; 2001 Jun; 24(6):666-70. PubMed ID: 11411556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
    Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
    Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.